Bringing Light to the Dark Side of Insulin
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
think it's remarkable that only a few months after Banting introduced insulin to the world of diabetes, on the heels of one of medicine's greatest discoveries, Elliot Joslin wrote, "insulin is not a cure for diabetes, but a potent preparation alike . . .for evil and for good."Today, 85 years later, with all the advances in insulin therapy, there is still a dark side to this potent preparation, and it is hypoglycemia.Hypoglycemia is the major barrier preventing insulin from achieving its full, therapeutic promise.My story begins 30 years ago.Bill Tamborlane came to me with a portable, battery-powered pump being used in pediatrics to infuse the iron-chelating drug desferrioxamine continuously via the subcutaneous route into children with thalassemia major.He hoped to use it to treat children with glycogen storage disease, a study we never performed.This relatively small pump, the Autosyringe Model AS2C, was at that time relatively unique.It had an "instant dose" button that allowed for bolus dose administration as well as the ability to deliver solutions continuously.In short, it was a "perfect" vehicle to infuse insulin in diabetes.Improved glucose control had been demonstrated earlier in the inpatient setting in type 1 diabetic patients given continuous intravenous insulin delivered at preprogrammed basal rates with increments before meals.Such systems were not practical outside of a controlled environment.This device, however, was small enough to be used for continuous subcutaneous insulin delivery.My enthusiasm for this idea was based on experiments Luigi Sacca and I performed 2 years earlier in the mid 1970s.We demonstrated that overnight basal insulin infusion in doses sufficient to normalize fasting glucose the next morning restored the ability of hyperglycemia to suppress hepatic glucose production in type 1 diabetic patients, despite their failure to release insulin (1).Those studies suggested that if insulin were delivered at more physiological basal rates (something that was not easy to achieve with the intermediate-acting insulin available at the time), it would not only provide better regulation of fasting glucose but also minimize postprandial hyperglycemia after a breakfast meal.The second study made me think that open-loop continuous insulin delivery might be relatively safe.In that study, we infused insulin to "conventionally" (which at that time was poorly) treated type 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The AMP‐Activated Protein Kinase: Fuel Gauge of the Mammalian Cell?
Hardie, D. G., & Carling, D. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00259.x · Cited by 1,317
Ablation of Insulin-Producing Neurons in Flies: Growth and Diabetic Phenotypes
Rulifson, E. J., Kim, S. K., & Nusse, R. (2002) · Science · doi:10.1126/science.1070058 · Cited by 1,064
Hypothalamic insulin signaling is required for inhibition of glucose production
Obici, S., Zhang, B. B., Karkanias, G., & Rossetti, L. (2002) · Nature Medicine · doi:10.1038/nm1202-798 · Cited by 904 · cited 2×
“The brain may also receive a signal from the islet to facilitate the suppression of hepatic glucose production (73) as well as glucagon secretion.”
BackgroundGerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
Long-term effect of diabetes and its treatment on cognitive function
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa066397 · Cited by 646
Heller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats
Spanswick, D., Smith, M. A., Mirshamsi, S., Routh, V. H., & Ashford, M. L. J. (2000) · Nature Neuroscience · doi:10.1038/77660 · Cited by 495
A model of the kinetics of insulin in man
Sherwin, R. S., Kramer, K. J., Tobin, J. D., Insel, P. A., Liljenquist, J. E., Berman, M., & Andres, R. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107697 · Cited by 460 · cited 2×
“This technique, developed a decade earlier when I worked as a postdoctoral fellow in the laboratory of Reuben Andres (10), allowed us to produce a standardized hypoglycemic stimulus, providing a means to compare responses between nondiabetic and diabetic subjects (11,12).”
MethodSelf-citationTong, Q., Ye, C., McCrimmon, R. J., Dhillon, H., Choi, B., Kramer, M. D., Yu, J., Yang, Z., Christiansen, L. M., Lee, C. E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.04.001 · Cited by 413 · cited 1×
“Based on recent data implicating ventromedial nucleus SF1 glutamate neurons in activating counterregulatory responses (49), it is intriguing to speculate that ventromedial nucleus SF1 glutamate neurons may be responsible for generating this downstream signal.”
BackgroundFanelli, C. G., Epifano, L., Rambotti, A. M., Pampanelli, S., Di Vincenzo, A., Modarelli, F., Lepore, M., Annibale, B., Ciofetta, M., Bottini, P., et al. (1993) · Diabetes · doi:10.2337/diab.42.11.1683 · Cited by 398 · cited 1×
“Subsequently, Geri Bolli’s group showed that HAAF could, over time, be reversed by scrupulous avoidance of hypoglycemia (18).”
Background
Cited by
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Stress as a Common Risk Factor for Obesity and Addiction
Sinha, R., & Jastreboff, A. M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.032 · Cited by 611
Hypoglycemia, Diabetes, and Cardiovascular Events
Desouza, C. V., Bolli, G. B., & Fonseca, V. (2010) · Diabetes Care · doi:10.2337/dc09-2082 · Cited by 443
Role of addiction and stress neurobiology on food intake and obesity
Sinha, R. (2018) · Biological Psychology · doi:10.1016/j.biopsycho.2017.05.001 · Cited by 211
Taborsky, G. J., & Mundinger, T. O. (2012) · Endocrinology · doi:10.1210/en.2011-2040 · Cited by 140
“(18), there have been few analogous studies in diabetic”
Background
Metadata
- Authors
- Sherwin, R. S.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-09-01
- Volume
- 57
- Issue
- 9
- Pages
- 2259-2268
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2123411875
- Cited by
- 55
- References
- 16
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bringing Light to the Dark Side of Insulin. https://app.cochat.ai/papers/10.2337/db08-9023
- The paper
- Sherwin, R. S. (2008). Bringing Light to the Dark Side of Insulin. Diabetes. https://doi.org/10.2337/db08-9023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.